10
Participants
Start Date
June 20, 2024
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2027
KYV-101 (Biological) - 0.33 ×10^8 cells
KYV-101 is a type of treatment called CAR T-cell therapy. It uses cells from your own immune system, called T-cells, to attack cells that cause inflammation. T-cells are a type of white blood cell.
KYV-101 (Biological) - 1 ×10^8 cells
KYV-101 is a type of treatment called CAR T-cell therapy. It uses cells from your own immune system, called T-cells, to attack cells that cause inflammation. T-cells are a type of white blood cell.
Chemotherapy: cyclophosphamide (CYC)
Participants will receive one 3-day cycle of lymphodepletion with CYC 300 mg/m2 prior to administration of KYV-101.
Chemotherapy: fludarabine (FLU)
Participants will receive one 3-day cycle of lymphodepletion with FLU 30 mg/m2 prior to administration of KYV-101.
University of California, San Francisco, Multiple Sclerosis Center, San Francisco
Collaborators (1)
Kyverna Therapeutics
INDUSTRY
Bruce Cree
OTHER